Use of dipeptidyl peptidase iv inhibitors for lowering the blood glucose level in mammals
Номер патента: CA2252576A1
Опубликовано: 06-11-1997
Автор(ы): Christopher H.S. Mcintosh, Fred Rosche, Hans-Ulrich Demuth, Jom Schmidt, Ray A. Pederson, Robert P. Pauly
Принадлежит: Christopher H.S. Mcintosh, Fred Rosche, Hans-Ulrich Demuth, Jom Schmidt, PROBIODRUG AG, Probiodrug Gesellschaft Fur Arzneimittelforschung Mbh, Prosidion Limited, Ray A. Pederson, Robert P. Pauly
Опубликовано: 06-11-1997
Автор(ы): Christopher H.S. Mcintosh, Fred Rosche, Hans-Ulrich Demuth, Jom Schmidt, Ray A. Pederson, Robert P. Pauly
Принадлежит: Christopher H.S. Mcintosh, Fred Rosche, Hans-Ulrich Demuth, Jom Schmidt, PROBIODRUG AG, Probiodrug Gesellschaft Fur Arzneimittelforschung Mbh, Prosidion Limited, Ray A. Pederson, Robert P. Pauly
Реферат: The present invention relates to a novel method in which reduction of the activity of the enzyme Dipeptidyl Peptidase (DP IV or CD 26), or of DP IV - like enzyme activity, in the blood of mammals by specific enzyme effectors will result in a reduced degradation of the endogenous, or exogenously administrated, insulinotropic peptides (incretins), Gastric Inhibitory Polypeptide Glucose-dependent Insulinotropic Polypeptide 1-42 (GIP1-2) and Glucagon-like Peptide 1 7-36 amide (GLP-1 7-36) (or analogs of these peptides). The decrease in concentration of these peptides or their analogs, resulting from degradation by DP IV and DP IV-like enzymes, will be thus be reduced or delayed. As a consequence of the enhanced stability of the endogenous, or exogenously administered, incretins or their analogs, caused by a reduction in DP IV-activity, their insulinotropic effects are enhanced, resulting in a potentate stimulation of insulin secretion from the pancreatic islets of Langerhans, and more rapid removal of glucose from the blood. As a result, glucose tolerance is improved. As a consequence, metabolic abnormalities associated with Diabetes mellitus, including abnormalities of carbohydrate and lipid metabolism, glucosuria and severe metabolic acidosis, and chronic alterations such as microvascular and macrovascular disease and polyneuropathy, which are the consequence of prolonged, elevated circulating glucose concentrations, are prevented or alleviated. The present invention is a new approach to lowering elevated concentrations of blood glucose. It is simple, commercially useful, and is suitable to be used in the therapy, especially of human diseases, which are caused by elevated or extraordinary blood glucose levels.
Use of effectors decreasing activity of dipeptidyl-peptidase (dp iv) and enzyme dp iv respectively with similar activity for decrease of blood glucose level
Номер патента: RU2189233C2. Автор: Ханс-Ульрих ДЕМУТ,Фред РОШЕ,Ерн ШМИДТ,Роберт П. ПОЛИ,Кристофер Г.С. МАКИНТОШ,Рэй А. ПЕДЕРСОН. Владелец: Пробиодруг Гезелльшафт Фюр Арцнаймиттельфоршунг Мбх. Дата публикации: 2002-09-20.